Page last updated: 2024-12-07

anisodine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

anisodine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123673
MeSH IDM0059074

Synonyms (2)

Synonym
anisodine
[(1r,2s,4r,5s)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2s)-2,3-dihydroxy-2-phenylpropanoate

Research Excerpts

Effects

ExcerptReferenceRelevance
"Anisodine has been reported to exert neuroprotective effects in cerebral ischemia/reperfusion (I/R) animal model."( Low Dose of Anisodine Hydrobromide Induced Neuroprotective Effects in Chronic Cerebral Hypoperfusion Rats.
Ao, H; Chen, D; Chen, Q; Liu, H; Peng, C; Wan, F; Xie, X; Zhang, S, 2017
)
1.56

Pharmacokinetics

ExcerptReferenceRelevance
" Clinical phenomena suggested that the changes of substituent group were related to the pharmacokinetic and pharmacodynamic characteristics of the agents."( Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats.
Chen, X; Li, C; Li, N; Liu, Q; Lu, Y; Ren, S; Tian, F; Wang, X; Zhao, D; Zhou, S, 2015
)
0.64

Compound-Compound Interactions

Anisodine combined with cytidine-5'-diphosp-bocholine (citicoline) in the treatment of early optic nerve contusion.

ExcerptReferenceRelevance
"To investigate the efficacy of anisodine combined with cytidine-5'-diphosp-bocholine (citicoline) in the treatment of early optic nerve contusion."( Efficacy of cytidine-5'-diphosp-bocholine combined with compound anisodine in the treatment of early optic nerve contusion.
Huang, J; Huang, Y; Jiang, J; Wang, W; Zhang, J, 2012
)
0.9
" The patients in the intervention group additionally received anisodine in combination with citicoline."( Efficacy of cytidine-5'-diphosp-bocholine combined with compound anisodine in the treatment of early optic nerve contusion.
Huang, J; Huang, Y; Jiang, J; Wang, W; Zhang, J, 2012
)
0.86

Bioavailability

ExcerptReferenceRelevance
" Because of their partial solubility, Atr, Ani, AT3, and Sco had different bioavailability in rats of 21."( Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats.
Chen, X; Li, C; Li, N; Liu, Q; Lu, Y; Ren, S; Tian, F; Wang, X; Zhao, D; Zhou, S, 2015
)
0.64
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (39.22)18.7374
1990's17 (33.33)18.2507
2000's6 (11.76)29.6817
2010's7 (13.73)24.3611
2020's1 (1.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.29 (24.57)
Research Supply Index3.99 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index25.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (3.92%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other49 (96.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy, Safety, And Tolerability Of Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine [NCT05416476]Phase 3288 participants (Anticipated)Interventional2023-09-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]